| Univariable Cox analysis in unmatched cohort | Univariable Cox analysis in matched cohort by PSM | ||
---|---|---|---|---|
Variables | HR (95%CI) | P valueb | HR (95%CI) | P valueb |
Intrathecal therapy | 0.55(0.3–0.99) | 0.045* | 0.50(0.27–0.95) | 0.035* |
Sex (Male) | 0.34(0.08–1.39) | 0.133 | 0.47(0.11–1.93) | 0.291 |
System involvement of SLE | ||||
 Mucocutaneous | 0.85(0.47–1.52) | 0.583 | 0.90(0.48–1.68) | 0.730 |
 Musculoskeletal | 0.72(0.4–1.28) | 0.265 | 0.78(0.42–1.44) | 0.426 |
 Pulmonary involvement | 1.46(0.62–3.43) | 0.391 | 1.42(0.6–3.37) | 0.431 |
 Cardiovascular involvement | 1.9(1.04–3.48) | 0.037* | 2.05 (1.07–3.92) | 0.031* |
 Hematological involvement | 1.08(0.6–1.94) | 0.791 | 0.92(0.49–1.72) | 0.797 |
 Lupus nephritis | 1.28(0.71–2.3) | 0.415 | 1.28(0.68–2.42) | 0.446 |
 Serositis | 2.2(1.16–4.17) | 0.016* | 2.01 (1.05–3.87) | 0.035* |
 SLEDAI-2K | 1.01(0.97–1.04) | 0.774 | 1.00(0.96–1.04) | 0.847 |
Subtype of NPSLE | ||||
 Headache | 0.5(0.23–1.07) | 0.074 | 0.48 (0.21–1.09) | 0.079 |
 Seizure disorder | 2.05(1.15–3.66) | 0.015* | 2.03 (1.1–3.75) | 0.024* |
 Acute confusional state | 3.73(2.03–6.87) | <0.001* | 3.55 (1.86–6.78) | <0.001* |
 Cerebrovascular disease | 0.69(0.25–1.91) | 0.471 | 0.84(0.3–2.36) | 0.742 |
 Mood disorder | 1.54(0.69–3.45) | 0.295 | 1.94(0.86–4.38) | 0.112 |
 Cognitive dysfunction | 0.73(0.29–1.85) | 0.507 | 0.89(0.35–2.28) | 0.812 |
 Aseptic meningitis | 0.39(0.05–2.86) | 0.358 | 0.94(0.68–3.56) | 0.906 |
 Anxiety | 0.91(0.13–6.6) | 0.924 | 1.25(0.17–9.08) | 0.827 |
 Psychosis | 0.71(0.72–4.63) | 0.386 | 0.77(0.34–1.74) | 0.528 |
 Myelopathy | 1.83(0.72–4.63) | 0.203 | 1.17(0.36–3.8) | 0.795 |
 Demyelinating syndrome | 1.68(0.52–5.43) | 0.385 | 1.50(0.46–4.86) | 0.503 |
 Guillain–Barré syndrome | 1.45(0.2–10.54) | 0.716 | 1.27 (0.17–9.27) | 0.816 |
 Mononeuropathy | 0(0–Inf) | 0.997 | 0(0–Inf) | 0.996 |
 Movement disorder | 1.3(0.31–5.37) | 0.716 | 1.43(0.35–5.95) | 0.620 |
 Cranial neuropathy | 1.11(0.27–4.58) | 0.884 | 1.39(0.34–5.77) | 0.649 |
 Plexopathy | 3.86(0.53–28.15) | 0.183 | 3.38(0.46–24.75) | 0.231 |
 Polyneuropathy | 1.72(0.68–4.35) | 0.255 | 1.50(0.53–4.24) | 0.441 |
Methylprednisolone pulse therapy | 1.03(0.57–1.86) | 0.922 | 0.96 (0.51–1.81) | 0.911 |
CYC use | 0.57 (0.32–1.00) | 0.051 | 0.63 (0.34–1.16) | 0.137 |
Increased ICPa | 0.91(0.51–1.62) | 0.753 | 0.78(0.42–1.46) | 0.440 |
Increased levels of protein in CSFb | 1.39(0.78–2.41) | 0.258 | 1.47(0.8–2.72) | 0.216 |
Abnormal CSF cytology | 1.13(0.45–2.87) | 0.793 | 1.17(0.41–3.3) | 0.771 |